Wegovy overview
Brand name for semaglutide 2.4 mg, FDA-approved for chronic weight management and cardiovascular risk reduction in adults with overweight/obesity + established CVD.
Wegovy at a glance
Manufacturer
Novo Nordisk
FDA status
FDA-approved
Questions readers ask
What is Wegovy approved for?
Wegovy is Novo Nordisk’s semaglutide 2.4 mg, FDA-approved for chronic weight management and for cardiovascular risk reduction in adults with overweight or obesity and established cardiovascular disease.
How much does Wegovy cost without insurance?
Via NovoCare (read October 14, 2026), the Wegovy pen is $349 a month, with new patients paying $199 for the first two fills through Dec 31, 2026. The Wegovy pill is $149, $199 or $299 a month depending on dose.
Can Medicare members get Wegovy for $50 a month?
Eligible Part D members can, through the Medicare GLP-1 Bridge, which runs July 1, 2026 to Dec 31, 2027 with a $50 copay, prior authorization and BMI-based criteria. Open enrollment runs Oct 15 to Dec 7, 2026.
How much weight did people lose on Wegovy’s dose in STEP 1?
In STEP 1, semaglutide 2.4 mg produced a mean −14.9% body-weight change at 68 weeks (treatment-policy estimand). Compounded semaglutide is a different, unapproved preparation and was not the product tested.
Primary sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026)
- FDA: Policies for compounders as GLP-1 supply stabilizes (updated April 1, 2026)
- FDA: Compounding and the FDA — questions and answers
- FDA: Registered outsourcing facilities (503B)
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021
- Wegovy (semaglutide) prescribing information, Novo Nordisk